Form 4: Bicara CFO Ivan Hyep Granted 125,000 Stock Options

Bicara Therapeutics Inc. Chief Financial Officer Ivan Hyep was granted 125,000 stock options with an exercise price of $16.76, vesting quarterly over four years.

Summary

• Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc. (BCAX), acquired 125,000 stock options.
• The transaction date for the option grant was February 2, 2026.
• The exercise price for these stock options is $16.76 per share.
• The options will vest in sixteen equal quarterly installments following February 2, 2026.
• Vesting is contingent upon Mr. Hyep's continued service to the company on each vesting date.
• The expiration date for these stock options is February 2, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive for corporate governance, aligning the CFO's long-term interests with shareholder value creation, which is a standard and healthy practice in executive compensation.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's long-term financial interests with those of the shareholders, incentivizing value creation.
• This is a standard practice in executive compensation, aiming to retain key talent and motivate performance over an extended period.

Negatives

• The future exercise of these options could lead to a degree of share dilution, although this is a common aspect of equity-based compensation plans.

Risks

• The vesting of the stock options is subject to the Reporting Person's continued service on each vesting date, meaning the options could be forfeited if employment ceases.

Future Outlook

The vesting schedule of the stock options over sixteen equal quarterly installments implies an expectation of continued service from the Chief Financial Officer, aligning his incentives with the company's long-term performance and strategic goals.

Industry Context

StockSavvy.ai notes that the grant of stock options to key executives like the CFO is a prevalent compensation strategy within the biotechnology and pharmaceutical sectors. This approach is designed to attract and retain top talent, incentivize long-term performance, and align executive interests with shareholder value creation, particularly in industries with long development cycles and significant R&D investments.

Comparison to Industry Standards

• Many emerging biotech companies, similar to Bicara Therapeutics, utilize equity-based compensation plans, including stock options, as a primary component of executive remuneration.
• The vesting schedule of quarterly installments over several years is a common structure, comparable to practices seen at companies like Moderna (MRNA) or BioNTech (BNTX) in their early growth phases, aiming to foster long-term commitment and performance.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased long-term value due to aligned executive incentives, balanced against potential future dilution from option exercise.
• Employees (specifically the CFO): Provides a significant long-term incentive and a direct stake in the company's success, contingent on continued employment.

Next Steps

• The stock options will vest in sixteen equal quarterly installments following February 2, 2026, subject to the CFO's continued service.

Key Dates

Keywords

Bicara Therapeutics, BCAX, Stock Options, Executive Compensation, Insider Transaction, Form 4, Ivan Hyep, CFO, Equity Grant